Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.40 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.38 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.38 |
| ▸ | EIF4H | Q15056 | 2/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 4/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | PLEC | Q15149 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL490331 | 0.86 | OPRD1 (0.53) | OPRM1OPRD1TP53LMNAHPGD | |
| SCHEMBL3966537 | 0.72 | SLC6A2 (0.38) | OPRM1CYP3A4HTTHPGD | |
| SCHEMBL490087 | 0.70 | OPRM1 (0.40) | OPRM1OPRD1PABPC1APOBEC3AEIF4H | |
| SCHEMBL3965155 | 0.69 | SLC6A2 (0.36) | OPRM1TP53LMNA | |
| SCHEMBL490580 | 0.69 | OPRM1 (0.48) | OPRM1OPRD1TP53 | |
| SCHEMBL489982 | 0.68 | OPRD1 (0.53) | OPRM1OPRD1MEN1KMT2ALMNA | |
| SCHEMBL31270719 | 0.68 | OPRD1 (0.53) | OPRM1OPRD1MEN1KMT2ALMNA | |
| SCHEMBL3384585 | 0.66 | CYP3A4 (0.33) | OPRM1OPRD1CYP3A4HTTCHRNA7 | |
| SCHEMBL3963787 | 0.65 | CHRNB2 (0.41) | CYP3A4 | |
| SCHEMBL490374 | 0.65 | OPRM1 (0.44) | OPRM1OPRD1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009860-A1 | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009860-A1 | Tricyclic delta-opioid modulators | OPRD1, OPRK1, OPRL1 | OPRM1 4/4885OPRD1 1/4885PABPC1 3535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.